Meeder Asset Management Inc. Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Meeder Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,490.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 525 shares of the biotechnology company’s stock after purchasing an additional 492 shares during the period. Meeder Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $83,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after acquiring an additional 120 shares in the last quarter. WCM Investment Management LLC increased its position in shares of Sarepta Therapeutics by 2.3% during the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after acquiring an additional 142 shares during the period. Finally, Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at $31,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 0.6 %

SRPT stock opened at $124.65 on Friday. The company has a market cap of $11.89 billion, a price-to-earnings ratio of 1,133.18 and a beta of 0.81. The company has a fifty day moving average price of $139.78 and a 200 day moving average price of $132.74. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the previous year, the business posted ($0.27) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on SRPT shares. Leerink Partners boosted their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, June 24th. Cantor Fitzgerald reduced their target price on shares of Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Morgan Stanley reiterated an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 21st. Barclays reduced their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Citigroup lowered their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $186.22.

Insider Buying and Selling at Sarepta Therapeutics

In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. Insiders sold a total of 52,801 shares of company stock valued at $8,399,586 in the last ninety days. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.